Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI - PACE-CME

Treatment with antiinflammatory agent reduces both first and recurrent events postMI

Media formats available:

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Recommended

Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
AHA 2019
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
AHA 2019
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
- Prof. Freek Verheugt, MD
Possible favorable effects of icosapent ethyl on plaque-parameters
Possible favorable effects of icosapent ethyl on plaque-parameters
AHA 2019
Possible favorable effects of icosapent ethyl on plaque-parameters
- Prof. Stephen Nicholls
Improved health status with SGLT2-inhibitor in HFrEF
Improved health status with SGLT2-inhibitor in HFrEF
AHA 2019
Improved health status with SGLT2-inhibitor in HFrEF
- Prof. Mikhail Kosiborod